B. Bolstad

1.5k total citations
31 papers, 1.1k citations indexed

About

B. Bolstad is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, B. Bolstad has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Radiology, Nuclear Medicine and Imaging, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in B. Bolstad's work include Radiopharmaceutical Chemistry and Applications (9 papers), Bone health and treatments (6 papers) and Radiation Dose and Imaging (5 papers). B. Bolstad is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (9 papers), Bone health and treatments (6 papers) and Radiation Dose and Imaging (5 papers). B. Bolstad collaborates with scholars based in Norway, Sweden and Netherlands. B. Bolstad's co-authors include Magne Røkkum, Sten Nilsson, Øyvind S. Bruland, Dag Clement Johannessen, Jan Tennvall, K. Pigott, Lars Franzén, Ulf Petersson, M. Sokal and Bo Lennernäs and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

B. Bolstad

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Bolstad Norway 16 523 520 316 313 120 31 1.1k
Ömer Uğur Türkiye 18 312 0.6× 331 0.6× 297 0.9× 200 0.6× 238 2.0× 65 1.0k
E. Kresnik Austria 22 658 1.3× 381 0.7× 611 1.9× 228 0.7× 90 0.8× 77 1.7k
Maureen A. Zivanovic United Kingdom 13 629 1.2× 468 0.9× 338 1.1× 438 1.4× 189 1.6× 32 1.2k
Massimo Castellani Italy 18 296 0.6× 266 0.5× 225 0.7× 141 0.5× 40 0.3× 77 843
Anton Staudenherz Austria 17 263 0.5× 247 0.5× 456 1.4× 171 0.5× 210 1.8× 62 1.1k
Young So South Korea 26 598 1.1× 641 1.2× 774 2.4× 247 0.8× 34 0.3× 111 2.2k
Simin Dadparvar United States 20 474 0.9× 356 0.7× 224 0.7× 195 0.6× 41 0.3× 62 1.0k
Tim Van den Wyngaert Belgium 24 644 1.2× 484 0.9× 463 1.5× 1.0k 3.3× 156 1.3× 98 2.3k
D. M. Ackery United Kingdom 21 643 1.2× 443 0.9× 519 1.6× 382 1.2× 60 0.5× 53 1.4k
Michael Hofmann Switzerland 12 235 0.4× 265 0.5× 181 0.6× 190 0.6× 66 0.6× 26 759

Countries citing papers authored by B. Bolstad

Since Specialization
Citations

This map shows the geographic impact of B. Bolstad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Bolstad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Bolstad more than expected).

Fields of papers citing papers by B. Bolstad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Bolstad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Bolstad. The network helps show where B. Bolstad may publish in the future.

Co-authorship network of co-authors of B. Bolstad

This figure shows the co-authorship network connecting the top 25 collaborators of B. Bolstad. A scholar is included among the top collaborators of B. Bolstad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Bolstad. B. Bolstad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tzogani, Kyriaki, Helga Haugom Olsen, Mats Ökvist, et al.. (2020). The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with anFLT3Mutation. The Oncologist. 25(7). e1070–e1076. 15 indexed citations
2.
3.
Moscetti, Luca, Paula B. van Hennik, B. Bolstad, et al.. (2020). Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. ESMO Open. 5(4). e000856–e000856. 1 indexed citations
4.
Tzogani, Kyriaki, Didier Meulendijks, Carla Herberts, et al.. (2019). European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. ESMO Open. 4(6). e000606–e000606. 14 indexed citations
5.
Reigstad, Ole, et al.. (2017). Five- to 10-Year Prospective Follow-Up of Wrist Arthroplasty in 56 Nonrheumatoid Patients. The Journal Of Hand Surgery. 42(10). 788–796. 47 indexed citations
6.
7.
Kolstad, Arne, Jostein Dahle, Caroline Stokke, et al.. (2014). A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. Blood. 124(21). 3094–3094. 3 indexed citations
8.
Nilsson, Sten, Lars Franzén, Christopher Parker, et al.. (2012). Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. Clinical Genitourinary Cancer. 11(1). 20–26. 90 indexed citations
9.
Reigstad, Ole, et al.. (2012). Promising one- to six-year results with the Motec wrist arthroplasty in patients with post-traumatic osteoarthritis. Journal of Bone and Joint Surgery - British Volume. 94-B(11). 1540–1545. 30 indexed citations
10.
11.
Nilsson, Stefan, et al.. (2009). Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined safety analyses of phase I and II clinical trials. 2 indexed citations
12.
Nilsson, Sten, Lars Franzén, Christopher Parker, et al.. (2007). Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology. 8(7). 587–594. 354 indexed citations
13.
Holm, Inger, et al.. (2000). Reliability of goniometric measurements and visual estimates of hip ROM in patients with osteoarthrosis. Physiotherapy Research International. 5(4). 241–248. 127 indexed citations
14.
15.
Tveit, Kjell M., et al.. (1994). Iodixanol in Cardioangiography. Acta Radiologica. 35(6). 614–618. 27 indexed citations
16.
Albrechtsson, U., et al.. (1994). Iodixanol in Femoral Arteriography. Acta Radiologica. 35(6). 629–631. 12 indexed citations
17.
Albrechtsson, U., Berit Calissendorff, Lars Norgren, et al.. (1994). Iodixanol in Femoral Arteriography. Acta Radiologica. 35(6). 629–631. 3 indexed citations
18.
Tveit, Kjell M., et al.. (1994). Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml.. PubMed. 35(6). 614–8. 33 indexed citations
19.
Andersen, Poul Erik, et al.. (1993). Iodixanol and ioxaglate in cardioangiography: A double-blind randomized phase III study. Clinical Radiology. 48(4). 268–272. 46 indexed citations
20.
Bolstad, B., K. W. Borch, Birthe H. Grynne, et al.. (1991). Safety and Tolerability of Iodixanol: A Dimeric, Nonionic Contrast Medium: An Emphasis on European Clinical Phases I and II. Investigative Radiology. 26. S201–S204. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ömer Uğur Breakdown of academic impact, for papers by E. Kresnik Breakdown of academic impact, for papers by Maureen A. Zivanovic Breakdown of academic impact, for papers by Massimo Castellani Breakdown of academic impact, for papers by Anton Staudenherz Breakdown of academic impact, for papers by Young So Breakdown of academic impact, for papers by Simin Dadparvar Breakdown of academic impact, for papers by Tim Van den Wyngaert Breakdown of academic impact, for papers by D. M. Ackery Breakdown of academic impact, for papers by Michael Hofmann
Rankless by CCL
2026